Resistant Alopecia Areata Treated with Tofacitinib

Several reports more so from western countries present recovery for alopecia areata (AA) with tofacitinib. In this report, we present the case of a young adult male diagnosed with resistant AA with failed treatment to oral as well topical steroids, minoxidil, and oral troxasalen. He was treated with...

Descripción completa

Detalles Bibliográficos
Autor principal: Sahay, Govind
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674063/
https://www.ncbi.nlm.nih.gov/pubmed/36404885
http://dx.doi.org/10.4103/ijt.ijt_63_22
_version_ 1784833073460805632
author Sahay, Govind
author_facet Sahay, Govind
author_sort Sahay, Govind
collection PubMed
description Several reports more so from western countries present recovery for alopecia areata (AA) with tofacitinib. In this report, we present the case of a young adult male diagnosed with resistant AA with failed treatment to oral as well topical steroids, minoxidil, and oral troxasalen. He was treated with tofacitinib 5 mg twice a day along with biotin supplement. Hair regrowth was observed at 1 month. After 3 months, nearly more than 90% hair regrowth was observed. No associated side effects were noted.
format Online
Article
Text
id pubmed-9674063
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-96740632022-11-19 Resistant Alopecia Areata Treated with Tofacitinib Sahay, Govind Int J Trichology Case Report Several reports more so from western countries present recovery for alopecia areata (AA) with tofacitinib. In this report, we present the case of a young adult male diagnosed with resistant AA with failed treatment to oral as well topical steroids, minoxidil, and oral troxasalen. He was treated with tofacitinib 5 mg twice a day along with biotin supplement. Hair regrowth was observed at 1 month. After 3 months, nearly more than 90% hair regrowth was observed. No associated side effects were noted. Wolters Kluwer - Medknow 2022 2022-10-07 /pmc/articles/PMC9674063/ /pubmed/36404885 http://dx.doi.org/10.4103/ijt.ijt_63_22 Text en Copyright: © 2022 International Journal of Trichology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Case Report
Sahay, Govind
Resistant Alopecia Areata Treated with Tofacitinib
title Resistant Alopecia Areata Treated with Tofacitinib
title_full Resistant Alopecia Areata Treated with Tofacitinib
title_fullStr Resistant Alopecia Areata Treated with Tofacitinib
title_full_unstemmed Resistant Alopecia Areata Treated with Tofacitinib
title_short Resistant Alopecia Areata Treated with Tofacitinib
title_sort resistant alopecia areata treated with tofacitinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674063/
https://www.ncbi.nlm.nih.gov/pubmed/36404885
http://dx.doi.org/10.4103/ijt.ijt_63_22
work_keys_str_mv AT sahaygovind resistantalopeciaareatatreatedwithtofacitinib

Ejemplares similares